LIPOSYN III 10% EMULSION

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

SOYBEAN OIL; EGG PHOSPHOLIPIDS

Available from:

HOSPIRA HEALTHCARE ULC

ATC code:

B05BA02

INN (International Name):

FAT EMULSIONS

Dosage:

100MG; 12MG

Pharmaceutical form:

EMULSION

Composition:

SOYBEAN OIL 100MG; EGG PHOSPHOLIPIDS 12MG

Administration route:

INTRAVENOUS

Units in package:

500ML

Prescription type:

Ethical

Therapeutic area:

CALORIC AGENTS

Product summary:

Active ingredient group (AIG) number: 0224198001; AHFS:

Authorization status:

CANCELLED POST MARKET

Authorization date:

2016-07-29

Summary of Product characteristics

PRODUCT MONOGRAPH
LIPOSYN
TM III 10%
LIPOSYN
TM III 20%
(soybean oil and egg phosphatide emulsion for injection)
10/1.2% w/v
20/1.2% w/v
Intravenous Nutrient Supplement
Hospira Healthcare Corporation
Date of preparation: April 14, 2011
111 Dr. Frederik Philips, suite 600
Saint-Laurent, Quebec
H4M 2X6
Control # 141415
NAMES OF DRUG
LIPOSYN
TM
III 10%
LIPOSYN
TM
III 20%
(soybean oil and egg phosphatide emulsion for injection)
10/1.2% w/v
20/1.2% w/v
THERAPEUTIC CLASSIFICATION
Intravenous Nutrient Supplement
ACTION
LIPOSYN
TM
III 10% and 20% (soybean oil and egg phosphatide emulsion for
injection)
provides the patient requiring parenteral nutrition with a source of
calories and the
essential fatty acids normally obtained from a nutritionally complete
oral diet. The
supplemental polyunsaturated fat prevents biochemical changes of
essential fatty acid
deficiency (EFAD) and prevents and reverses EFAD clinical
manifestations (scaliness of
skin, growth retardation, poor wound healing, sparse hair growth). The
infused fat
particles are cleared from the bloodstream in a manner thought to be
similar to the
clearing of chylomicrons.
INDICATIONS AND CLINICAL USE
LIPOSYN
TM
III 10% and 20% (soybean oil and egg phosphatide emulsion for
injection)
are indicated as sources of calories for patients requiring parenteral
nutrition. This
includes pre- and post-operative nutritional disorders and nutritive
disorders resulting
from decreased or inhibited intestinal absorption, as with tumours of
the digestive tract,
or in ulcerative colitis and terminal ileitis.
LIPOSYN
TM
III 10% and 20% are also indicated in burn cases, where nitrogen loss
can
be excessive, in prolonged states of unconsciousness if tube feeding
is inadvisable and in
cachexia due to serious diseases other than of the alimentary tract.
Where such nutrition is required for extended periods of time (more
than five days),
LIPOSYN
TM
III 10% and 20% are also indicated as sources of essential fatty acids
to
prevent or reverse biochemical changes in fatty acid composition of